Exicure (XCUR) Operating Margin (2016 - 2024)

Exicure's (XCUR) quarterly Operating Margin came in at 167.2% in Q1 2024, down 295.8% on a QoQ basis from 85.4% in Q4 2022.

Exicure (XCUR) Operating Margin (2016 - 2024) Analysis & Trends

Exicure (XCUR) has 8 years of Operating Margin data on file, last reported at 167.2% in Q1 2024.

Quarterly Operating Margin changed N/A year-over-year to 167.2% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 2446.4% (changed N/A YoY) and the FY2024 annual result came in at 2446.4%, changed N/A from the prior year.
Operating Margin eased to 167.2% in Q1 2024, from 85.4% in the prior quarter.
In the past five years, Operating Margin ranged from a high of 634.99% in Q4 2021 to a low of 17546.84% in Q2 2021.
A 4-year average of 2235.5% and a median of 301.64% in 2022 frame the typical range for Operating Margin.
Annual changes were most pronounced in 2020 — Operating Margin surged 2231782 bps — and 2021, when it slumped 1745626 bps.
Tracing XCUR's Operating Margin over 4 years: stood at 8900.0% in 2020, then surged by 107 bps to 634.99% in 2021, then slumped by 87 bps to 85.4% in 2022, then tumbled by 296 bps to 167.2% in 2024.
The last three Operating Margin figures came in at 167.2% (Q1 2024), 85.4% (Q4 2022), and 258.18% (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Exicure	8.41 Mn	8.41 Mn	-	-

Download Data